545 related articles for article (PubMed ID: 18501678)
21. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
22. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
[TBL] [Abstract][Full Text] [Related]
23. Gammadelta T-lymphocyte cytotoxic activity against Mycobacterium bovis analyzed by flow cytometry.
Olin MR; Hwa Choi K; Lee J; Molitor TW
J Immunol Methods; 2005 Feb; 297(1-2):1-11. PubMed ID: 15777926
[TBL] [Abstract][Full Text] [Related]
24. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
25. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells.
Bowles JA; Weiner GJ
J Immunol Methods; 2005 Sep; 304(1-2):88-99. PubMed ID: 16109421
[TBL] [Abstract][Full Text] [Related]
26. Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation.
Pfeiffer M; Stanojevic S; Feuchtinger T; Greil J; Handgretinger R; Barbin K; Jung G; Martin D; Niethammer D; Lang P
Bone Marrow Transplant; 2005 Jul; 36(2):91-7. PubMed ID: 15908973
[TBL] [Abstract][Full Text] [Related]
27. Peripheral blood gamma-delta T cells lyse fresh human brain-derived oligodendrocytes.
Freedman MS; Ruijs TC; Selin LK; Antel JP
Ann Neurol; 1991 Dec; 30(6):794-800. PubMed ID: 1838679
[TBL] [Abstract][Full Text] [Related]
28. Apparent sensitivity of human K lymphocytes to the spatial orientation and organization of target cell-bound antibodies as measured by the efficiency of antibody-dependent cellular cytotoxicity (ADCC).
Christiaansen JE; Burnside SS; Sears DW
J Immunol; 1987 Apr; 138(7):2236-43. PubMed ID: 3549899
[TBL] [Abstract][Full Text] [Related]
29. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
Lefebvre ML; Krause SW; Salcedo M; Nardin A
J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334
[TBL] [Abstract][Full Text] [Related]
30. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.
Niwa R; Sakurada M; Kobayashi Y; Uehara A; Matsushima K; Ueda R; Nakamura K; Shitara K
Clin Cancer Res; 2005 Mar; 11(6):2327-36. PubMed ID: 15788684
[TBL] [Abstract][Full Text] [Related]
31. Migratory pathways of gammadelta T cells and response to CXCR3 and CXCR4 ligands: adhesion molecules involved and implications for multiple sclerosis pathogenesis.
Poggi A; Zancolli M; Catellani S; Borsellino G; Battistini L; Zocchi MR
Ann N Y Acad Sci; 2007 Jun; 1107():68-78. PubMed ID: 17804534
[TBL] [Abstract][Full Text] [Related]
32. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.
Leidi M; Gotti E; Bologna L; Miranda E; Rimoldi M; Sica A; Roncalli M; Palumbo GA; Introna M; Golay J
J Immunol; 2009 Apr; 182(7):4415-22. PubMed ID: 19299742
[TBL] [Abstract][Full Text] [Related]
33. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
[TBL] [Abstract][Full Text] [Related]
34. The regulatory role of natural killer cells in multiple sclerosis.
Takahashi K; Aranami T; Endoh M; Miyake S; Yamamura T
Brain; 2004 Sep; 127(Pt 9):1917-27. PubMed ID: 15229129
[TBL] [Abstract][Full Text] [Related]
35. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.
de Romeuf C; Dutertre CA; Le Garff-Tavernier M; Fournier N; Gaucher C; Glacet A; Jorieux S; Bihoreau N; Behrens CK; Béliard R; Vieillard V; Cazin B; Bourel D; Prost JF; Teillaud JL; Merle-Béral H
Br J Haematol; 2008 Mar; 140(6):635-43. PubMed ID: 18302712
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of gammadelta T cell-induced human oligodendrocyte cytotoxicity: relevance to multiple sclerosis.
Zeine R; Pon R; Ladiwala U; Antel JP; Filion LG; Freedman MS
J Neuroimmunol; 1998 Jul; 87(1-2):49-61. PubMed ID: 9670845
[TBL] [Abstract][Full Text] [Related]
37. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
[TBL] [Abstract][Full Text] [Related]
38. Flow cytometric assay detecting cytotoxicity against human endogenous retrovirus antigens expressed on cultured multiple sclerosis cells.
Møller-Larsen A; Brudek T; Petersen T; Petersen EL; Aagaard M; Hansen DT; Christensen T
Clin Exp Immunol; 2013 Sep; 173(3):398-410. PubMed ID: 23656307
[TBL] [Abstract][Full Text] [Related]
39. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.
Maloney DG
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S19-26. PubMed ID: 15786022
[TBL] [Abstract][Full Text] [Related]
40. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils.
Shibata-Koyama M; Iida S; Misaka H; Mori K; Yano K; Shitara K; Satoh M
Exp Hematol; 2009 Mar; 37(3):309-21. PubMed ID: 19218011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
